In this episode, we dive into the transformational testimonial of Cesar Marin’s experience with microdosing. Once a CNN TV producer, and now a full time advocate for the power of intentional microdosing, Cesar shares with us his journey and how it helped transform his life.
Are the benefits of psychedelic microdosing all in our heads? A new study looks at the results compared to placebo. The results might shock you.
How long until Psychedelic Stocks Payoff?🍄🚀
To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
While researching a possible investment into psychedelic stocks, you have almost certainly heard the refrain of, “It’s a long-term investment.” I myself, in my many videos for The Psychedelic Investor and articles for PsychedelicSpotlight.com, have probably said this over 100 times.
And while the thesis for investing in psychedelic stocks is appealing, having a timeline clearer than “it’s a long term investment” is necessary before deciding whether it is worth the risk.
In this video, therefore, I endeavor to answer a big question: “When will psychedelic stocks provide a significant return on investment?”
Or, translated to Reddit-speak: when moon?
To start, I feel it’s necessary to give the warning that the answer may be never. To be clear, while I personally believe in the potential for psychedelic stocks such as MindMed (Nasdaq: MNMD, NEO: MMED) and Cybin (NYSE: CYBN, NEO: CYBN), the entire psychedelic medicines industry is inherently speculative and there is no guarantee of success. Yes, the science right now suggests that treatments such as MDMA therapy for PTSD and Ketamine therapy for addiction will disrupt the mental healthcare market, but this needs to be confirmed in larger studies.
There will be two separate turning points for psychedelic medicines and the companies that produce them: the legalization of the first psychedelic medicines, and the legalization of improved next-generation psychedelics.
The first will happen relatively soon.
#PsychedelicStocks #MindMed #Cybin
Petitioning the DEA to respect the ‘Right to Try Laws’ which empower terminally ill patients to legally access psilocybin therapy.
In recent years, the mental health and cognitive benefits of…
“The potential market for microdosing could be absolutely enormous because it is easier, more convenient, and more familiar,” says Mindset Pharma CEO James Lanthier.
Mycologist Paul Stamets’ legacy will forever be remembered with a species bearing his name – Psilocybe stametsii.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
